JPWO2016039398A1 - 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物 - Google Patents

含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物 Download PDF

Info

Publication number
JPWO2016039398A1
JPWO2016039398A1 JP2016547489A JP2016547489A JPWO2016039398A1 JP WO2016039398 A1 JPWO2016039398 A1 JP WO2016039398A1 JP 2016547489 A JP2016547489 A JP 2016547489A JP 2016547489 A JP2016547489 A JP 2016547489A JP WO2016039398 A1 JPWO2016039398 A1 JP WO2016039398A1
Authority
JP
Japan
Prior art keywords
group
compound
methyl
ethyl
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016547489A
Other languages
English (en)
Japanese (ja)
Inventor
望月　秀樹
秀樹 望月
佐々木　勉
勉 佐々木
其静 鐘
其静 鐘
新一 上里
新一 上里
佳之 平田
佳之 平田
孝明 住吉
孝明 住吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka University NUC
Kansai University
Original Assignee
Osaka University NUC
Kansai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Kansai University filed Critical Osaka University NUC
Publication of JPWO2016039398A1 publication Critical patent/JPWO2016039398A1/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2016547489A 2014-09-09 2015-09-09 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物 Pending JPWO2016039398A1 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2014183239 2014-09-09
JP2014183235 2014-09-09
JP2014183235 2014-09-09
JP2014183239 2014-09-09
PCT/JP2015/075660 WO2016039398A1 (fr) 2014-09-09 2015-09-09 Dérivé hétérocyclique contenant de l'azote, agent neuroprotecteur, et composition pharmaceutique pour le traitement du cancer

Publications (1)

Publication Number Publication Date
JPWO2016039398A1 true JPWO2016039398A1 (ja) 2017-06-15

Family

ID=55459142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016547489A Pending JPWO2016039398A1 (ja) 2014-09-09 2015-09-09 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物

Country Status (2)

Country Link
JP (1) JPWO2016039398A1 (fr)
WO (1) WO2016039398A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081624B2 (en) 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017014170A1 (fr) 2015-07-17 2017-01-26 武田薬品工業株式会社 Composé hétérocyclique
CA2992700A1 (fr) 2015-07-17 2017-01-26 Takeda Pharmaceutical Company Limited Derives oxadiazole utiles en tant qu'inhibiteurs de hdac
EP3342772A4 (fr) * 2015-08-25 2019-03-27 Takeda Pharmaceutical Company Limited Composé hétérocyclique
TW201910328A (zh) 2017-07-31 2019-03-16 日商武田藥品工業股份有限公司 雜環化合物
PE20220711A1 (es) 2019-09-27 2022-05-04 Takeda Pharmaceuticals Co Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2736200T3 (es) * 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos

Also Published As

Publication number Publication date
WO2016039398A1 (fr) 2016-03-17

Similar Documents

Publication Publication Date Title
JP7057798B2 (ja) ｍＴＯＲＣ１阻害剤
WO2016039398A1 (fr) Dérivé hétérocyclique contenant de l'azote, agent neuroprotecteur, et composition pharmaceutique pour le traitement du cancer
JP4405602B2 (ja) ヒストン脱アセチル化酵素阻害剤
US20190194207A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
EP2262808B1 (fr) Modulateurs du récepteur de la chimiokine
WO2021027911A1 (fr) Nouvel inhibiteur de k-ras g12c spirocyclique
JPH11335375A (ja) ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
CA2996682A1 (fr) Compose de pyrimidine fusionnee ou sel dudit compose
KR20180088462A (ko) 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체
CA3007699A1 (fr) Derives de perhydropyrrolo[3,4-c]pyrrole substitues et leur utilisation
JP2018502841A (ja) Ｈｄａｃ１／２阻害剤としてのピペリジン誘導体
CN116457344A (zh) 低分子量蛋白质降解剂及其应用
TW201625620A (zh) 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
CN110914253B (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
US9724331B2 (en) Use of maleimide derivatives for preventing and treating leukemia
KR102001431B1 (ko) 세포괴사 저해제로서의 인돌아미드 화합물
US20140045842A1 (en) Method for treating an inflammatory disease by administering a 1,2,3,4-tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent
CN112243437A (zh) 含丙烯酰基的核转运调节剂及其用途
KR102117083B1 (ko) 벤조헤테로사이클 화합물 및 이를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
US20220332722A1 (en) Perk inhibiting compounds
CN107556316B (zh) 含桥环的咪唑衍生物
KR101995533B1 (ko) [1,2,4]트리아졸로[4,3-a]퀴노잘린 아미노 페닐 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020233716A1 (fr) Inhibiteurs de kinase imidazopyridazine mnk1/mnk2, procédé de préparation correspondant et utilisation associée
EP1433789A1 (fr) Pyrrolopyrazines et leur utilisation comme inducteurs sélectifs d'apoptose